Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales ...

Eli Lilly said its tirzepatide franchise had another stellar quarter.

Surging consumer demand for blockbuster weight-loss drugs helped offset their declining prices.

By Mariam Sunny April 30 (Reuters) - The U.S. Food and Drug Administration on Thursday proposed excluding Novo Nordisk and ...

Foundayo became available on April 9 and has already reached 20,000 patients as Eli Lilly builds its marketing machine for ...

By Christy Santhosh and Mrinalika Roy April 30 (Reuters) - Eli Lilly hiked its full-year profit and revenue forecasts on ...

After just a few weeks on the market, thousands are already on Foundayo, Eli Lilly's oral weight loss pill. The drugmaker is ...

Eli Lilly (LLY) has cemented its status as the world's leading pharmaceutical company as it produced a stellar set of Q1 2026 ...

Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.

The Indianapolis-based drugmaker reported profit of $7.4 billion for the first quarter, up from $2.8 billion in the same period a year earlier.

A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for ...